Merck's patent on Finasteride (for the treatment of BPH) expired on June 19, 2006. [1] Merck was awarded a special license for the use of Finasteride to treat Male pattern Baldness. This patent is set to expire in November 2013. [2]
Some companies outside the U.S. currently manufacture generic finasteride and sell it at a lower cost than Merck:
* Ajanta Pharma (trade name Appecia)
* Aleppo Pharmaceutical (trade name Prosteride)
* Cipla (trade names Fincar and Finpecia)
* Dr. Reddy's (trade names Finax and Finast)
* Intas Pharmaceuticals (trade name Finalo)
* Ranbaxy (trade name Finara)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment